B-cell receptor specific for measles, mumps, and rubella viral antigens (MMR-specific BCR)

B-cell receptors (BCRs) specific for measles, mumps, and rubella viral antigens are specialized membrane-bound immunoglobulins expressed on the surface of B lymphocytes. These receptors play a critical role in the adaptive immune system by recognizing specific epitopes on the surface proteins of the measles (H and F proteins), mumps (HN and F proteins), and rubella (E1 and E2 proteins) viruses (WHO, 2023). Upon binding to their cognate antigens—typically delivered via live-attenuated vaccines like M-M-R II or Priorix—these BCRs trigger intracellular signaling pathways that lead to B-cell activation, clonal expansion, and differentiation into antibody-secreting plasma cells and memory B cells (FDA, 2023). This process is fundamental to establishing long-term humoral immunity and preventing infection by these highly contagious viral pathogens (CDC, 2021). Monitoring the activation and repertoire of these specific BCRs is essential for evaluating vaccine efficacy and understanding the longevity of immune protection. Safety considerations for targeting these receptors via vaccination include potential allergic reactions to vaccine stabilizers and the contraindication in certain immunodeficient populations.

Other names

Measles-mumps-rubella specific B-cell receptorAntigen-specific B-cell receptorSurface immunoglobulin for MMR antigensMMR-specific BCR

The vaccine antigens bind to and cross-link specific B-cell receptors on naive B cells, triggering intracellular signaling cascades (e.g., via Lyn, Syk, and PLC-gamma-2) that lead to B-cell proliferation, affinity maturation in germinal centers, and differentiation into long-lived plasma cells and memory B cells (Janeway et al., 2017; PubMed: 28418830).